Shots:

• The NICE has issued a final appraisal determination (FAD) which recommends Dupixent (dupilumab) as an add-on maintenance treatment for severe asthma
• The NICE recommendation is based on a LIBERTY ASTHMA QUEST trial evaluating Dupixent vs PBO in patients with severe asthma with high exacerbation rates and high biomarkers indicating type 2 inflammation
• The results showed a ~67% reduction in severe asthma attacks & 50% hospitalisations/A&E visits. The therapy also improved lung function (FEV1) & eliminated the use of OCS  (52% vs 29%) in patients with type 2 inflammation. The publication date of a NICE final guidance for dupilumab within NHS England is expected in early Dec.

  | Ref: PR Newswire | Image: Evaluate Pharma